A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Summary

The goal of this clinical research study is to find the highest tolerable dose of PROHIBITIN-TP01 that can be given to patients with advanced prostate cancer for which there are no standard therapy options. The safety of this drug will also be studied.

Timeline

Start

2012-05-24

Primary completion

2019-01-02

Completion

2019-01-02

Outcome

Outcome not reported

Stopped: “Terminated per PI's request”

Drugs

Indications